Revolution Medicines 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- The FDA approved RASONQ on August 26th for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy, and Revolution Medicines immediately began U.S. commercialization.
- RASONQ generated $197.6 million in net product revenue in the 3rd quarter of 2026, a partial quarter of approximately 5 weeks that included initial channel stocking; management also described revenue as $198 million and reported more than 5,000 unique patients treated on a commercial basis.
- The company ended the quarter with less than 2 weeks of channel inventory and expects to manage inventory at approximately 2 weeks over the long run.
- The gross-to-net discount was at the lower end of the anticipated 20% to 30% range; cost of sales was $0.3 million and was not representative of normalized cost of sales.
- R&D expenses were $417.1 million, compared with $262.5 million in the 3rd quarter of 2025, and SG&A expenses were $153.3 million, compared with $52.8 million in the 3rd quarter of 2025.
- Net loss was $407.5 million, compared with $305.2 million in the 3rd quarter of 2025, and included a non-cash charge of $40.7 million related to a change in the fair value of warrants assumed as part of the EQRX acquisition.
- The company ended the quarter with $3.7 billion in cash, cash equivalents, and marketable securities, excluding $250 million received in October under the first debt tranche of its funding arrangement with Royalty Pharma; it elected not to draw the optional 3rd royalty tranche.
- The NCCN guidelines include RASONQ as a Category 1 preferred subsequent therapy option for appropriate patients with locally advanced or metastatic pancreatic cancer and recurrent disease following prior systemic therapy; in metastatic non-small cell lung cancer, the guidelines include it as a Category 2A available targeted agent for specified RAS mutations.
- The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for Diraxon-RASIB as monotherapy for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy; the European Commission decision remains pending.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Revolution Medicines Q3 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Ryan Asay, Senior Vice President Corporate Affairs.
Please go ahead. Thank you, and welcome everyone to the third quarter 2026 earnings call.
Joining me on today's call are Dr. Mark Goldsmith, Revolution Medicines Chairman and Chief Executive Officer, Anthony Mancini, our Chief Global Commercialization Officer, Dr. Alan Sandler, our Chief Development Officer, and Jack Anders, our Chief Financial Officer. Dr. Wei Lin, our Chief Medical Officer, will join us for the Q&A portion of today's call. We would like to inform you that certain statements we make during this call will be forward-looking because such statements deal with future events and are subject to many risks and uncertainties. Actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our recent periodic report that has been filed with the U.S. Securities and Exchange Commission. This afternoon, we released financial results for the quarter ended September 30, 2026, and recent corporate updates.
The press release and updated corporate presentation are available on the investors section of our website at revmed.com. With that, I will turn the call over to our Chief Executive Officer, Dr. Mark Goldsmith.
Mark? Thank you, Ryan, and good afternoon, everyone.
I will begin today with several remarks focused on our progress in pancreatic cancer and across our broader RAS(ON) portfolio. Anthony will then provide an update on the initial launch of RASONQUE. Alan will discuss progress across our clinical development programs, and Jack will review our third quarter financial results before our return with brief concluding remarks. The third quarter marked a transformational period for Revolution Medicines. On August 26, less than two years after enrollment began in the global randomized RASolute 302 clinical trial, the FDA approved RASONQUE for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy, and we immediately began making it available by prescription in the United States.
The approval provided an important regulatory proof point for our RAS(ON) approach and marked the beginning of a new chapter for our company. More importantly, eligible patients and their physicians now have an approved oral targeted medicine designed to directly and broadly inhibit RAS, the main cause of pancreatic cancer, in a disease with a profound need for therapeutic breakthrough. This milestone reflects years of scientific conviction, disciplined development, and focused execution by our team and collaborators. It also formally opens the delivery phase of responsibility for Revolution Medicines. We are working tirelessly to execute the U.S. launch with urgency, help eligible patients access RASONQUE promptly, and support a positive treatment experience, and rigorously prepare to expand the launch internationally. With the U.S. approval in hand and our execution plans operational, the foundation in pancreatic cancer is being further reinforced by guideline recognition.
The NCCN Guidelines are more expansive than the approved label and now include RASONQUE as a category 1 preferred subsequent therapy option for appropriate patients with locally advanced or metastatic pancreatic cancer, as well as recurrent disease following prior systemic therapy. In metastatic pancreatic cancer, we believe this guideline placement highlights the strength and relevance to medical practice of RASONQUE and supports the use of RASONQUE in the FDA-approved settings. Importantly, NCCN's recommendation for treatment in locally advanced disease extends its recommendation beyond the FDA-approved metastatic disease setting, while its first-line metastatic listing recognizes RASONQUE as a useful in certain circumstances option with the applicable category linked to prescriber's assessment of performance status.
While these NCCN placements do not change the FDA-approved indication, they reflect NCCN's independent evaluation of the clinical data for RASONQUE in the context of significant unmet needs among patients with advanced pancreatic cancer. Based on the totality of clinical evidence, we believe RASONQUE is well-positioned to become a new global standard of care option for appropriate patients with advanced pancreatic cancer. This progress indicates significant momentum in our pursuit of bold ambitions in pancreatic cancer through a multi-asset strategy designed to extend RAS(ON) inhibition as the core of treatment in earlier lines of therapy and additional disease settings in which RAS is a key cancer driver. Recent regulatory designations further underscore the momentum. The FDA granted Breakthrough Therapy designation for the investigational combination of RASONQUE with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer.
In addition, the FDA granted orphan drug designation to zoldonrasib for the treatment of pancreatic cancer. We are conducting four additional global phase III studies across first-line metastatic and adjuvant pancreatic cancer, including programs evaluating two distinct regimens in first-line RAS G12D pancreatic cancer: zoldonrasib plus chemotherapy and the novel RAS(ON) inhibitor doublet of RASONQUE plus zoldonrasib. While each of these regimens remains investigational, together they reflect our determination to develop multiple potential best-in-class options for patients across the pancreatic cancer continuum. The growing body of evidence is also beginning to drive impact beyond pancreatic cancer. During the quarter, based on promising phase I/II clinical evidence for RASONQUE in previously treated RAS-mutant non-small cell lung cancer, the NCCN Guidelines recommended RASONQUE as a category 2A available targeted agent for patients with metastatic non-small cell lung cancer harboring KRAS G12, G13, or Q61 mutations.
While RASONQUE remains investigational in non-small cell lung cancer, this is an important treatment recommendation in RAS-mutant non-small cell lung cancer, where substantial unmet need remains. Later, Alan Sandler will provide an update on RASolve 301, a phase III study of RASONQUE in RAS-mutant non-small cell lung cancer, and our broader development strategy in non-small cell lung cancer. We are highly encouraged that the EMA's Committee for Medicinal Products for Human Use, or CHMP, has also moved rapidly to adopt a positive opinion for daraxonrasib as a monotherapy indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. For eligible patients in the European Union living with metastatic pancreatic cancer, a disease where profound unmet need persists, this opinion is a major step toward the potential availability of a new targeted medicine.
The unprecedented clinical benefit shown in RASolute 302 provides the foundation for this milestone, with superior efficacy versus chemotherapy, along with a manageable safety profile and favorable patient-reported outcomes. Together with the U.S. approval, the CHMP opinion advances our broader ambition to bring the potential benefits of RAS(ON) inhibition to patients around the world. The European Commission decision remains pending. Anthony Mancini will discuss the work underway to prepare for country-level access following a potential approval. With that, I'll turn the call over to Anthony for an update on the initial launch of RASONQUE and our commercial readiness outside the U.S.
Anthony? Thank you, Mark. The U.S. launch of RASONQUE is off to a strong start.
At approval, we outlined three priorities: enabling healthcare providers and eligible patients to achieve a positive treatment experience, ensuring broad coverage and seamless patient access with coordinated support, and establishing RASONQUE as a new standard of care for eligible patients with metastatic pancreatic cancer. Early in the launch, we're encouraged by the progress we're seeing against each of these priorities. RASONQUE generated net product revenue of $198 million for the quarter, reflecting more than 5,000 unique patients treated on a commercial basis. As a reminder, FDA approval occurred on August 26th, so these results reflect approximately five weeks of commercialization activity. Demand in the quarter reflected three components. First, demand included the transition of patients from our U.S. expanded access program to commercial supply. That transition is now complete for U.S. patients continuing treatment.
We prioritized continuity of care and successfully supported patients in obtaining their medication through the transition. Second, separate from the expanded access program transition, early commercial demand included a sizable cohort of patients who had exhausted available treatment options at the time of approval and were waiting for a new treatment option, including patients later in their treatment journey. And third, following approval, we began serving new eligible patients initiating RASONQUE. We're encouraged by the speed with which we were able to begin serving patients following approval, which reflects the significant unmet need in metastatic pancreatic cancer, the strength of RASONQUE's clinical profile and label, the strong launch readiness and initial execution across functions, as well as payer engagement and patient support in line with our expectations. These early results are highly encouraging.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
21 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
